Literature DB >> 16676402

Gene expression in poorly differentiated papillary thyroid carcinomas.

Øystein Fluge1, Ove Bruland, Lars A Akslen, Johan R Lillehaug, Jan E Varhaug.   

Abstract

We used cDNA microarrays to study gene expression in fresh frozen papillary thyroid carcinoma (PTC) specimens. Seven clinically aggressive carcinomas were included, comprising poorly differentiated PTC and tumors with extensive local invasion or synchronous distant metastases. Ten differentiated (classic) papillary thyroid carcinomas (PTC) and non-neoplastic thyroid tissues were also investigated. TaqMan quantitative reverse transcriptase-polymerase chain reaction (RT-PCR), in situ hybridization, and immunohistochemistry verified the differential gene expression. The B-Raf gene was mutated with a T-->A transversion at nucleotide 1799 (V600E) in 8 of 10 differentiated PTC, and in 4 of 7 aggressive carcinomas. Among genes markedly and equally over-expressed in carcinomas of both the aggressive and classic PtC groups, compared to normal thyroid tissue, were CBP/p300 transactivator (CItED1), fibronectin, growth/differentiation factor 15, potassium inwardly rectifying channel KCNJ2, glutaminyl peptide cyclotransferase, WNT7A, and dipeptidyl peptidase IV. A marked upregulation in carcinomas of P-cadherin mRNA and protein concomitant with E-cadherin downregulation, indicates a possible P-E cadherin "switch" in PTC. The growth factor homologue Nel-like 2, dual specificity phosphatase 5, the serine protease kallikrein 10, and also the tight junction genes claudin 1 and claudin 16, were upregulated in classic PTC but not in aggressive tumors, which may be consistent with altered cell polarity in the dedifferentiated PtC. The aggressive, poorly differentiated PtC group was specifically characterized by marked upregulation of several genes related to cell proliferation such as cell division cycle 2 (CDC2), CDC7, kinesin-like 5, ubiquitin conjugating enzyme E2C, and topoisomerase IIalpha, and by upregulation of genes encoding extracellular matrix proteins such as seprase, extracellular matrix protein 1, and several collagens. These aggressive tumors were also characterized by overexpression of the integrin ligand periostin, and in some biopsies also of osteopontin and of the upstream Rac-regulator dedicator of cytokinesis 10 (DOCK10). These data are interpreted to be consistent with altered cell motility, extracellular matrix remodeling and increased cell proliferation, as important processes in PTC tumor progression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16676402     DOI: 10.1089/thy.2006.16.161

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  56 in total

1.  Nanog and Oct4 overexpression increases motility and transmigration of melanoma cells.

Authors:  Aurelie Borrull; Stephanie Ghislin; Frederique Deshayes; Jessica Lauriol; Catherine Alcaide-Loridan; Sandrine Middendorp
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-11       Impact factor: 4.553

2.  RasGRF suppresses Cdc42-mediated tumour cell movement, cytoskeletal dynamics and transformation.

Authors:  Fernando Calvo; Victoria Sanz-Moreno; Lorena Agudo-Ibáñez; Fredrik Wallberg; Erik Sahai; Christopher J Marshall; Piero Crespo
Journal:  Nat Cell Biol       Date:  2011-06-19       Impact factor: 28.824

3.  Expression of papillary thyroid carcinoma-associated molecular markers and their significance in follicular epithelial dysplasia with papillary thyroid carcinoma-like nuclear alterations in Hashimoto's thyroiditis.

Authors:  Heng Ma; Jin Yan; Chao Zhang; Shenghui Qin; Lingzhi Qin; Liwei Liu; Xi Wang; Naping Li
Journal:  Int J Clin Exp Pathol       Date:  2014-10-15

4.  Gemigliptin, a novel dipeptidyl peptidase-IV inhibitor, exerts a synergistic cytotoxicity with the histone deacetylase inhibitor PXD101 in thyroid carcinoma cells.

Authors:  S H Kim; J G Kang; C S Kim; S-H Ihm; M G Choi; H J Yoo; S J Lee
Journal:  J Endocrinol Invest       Date:  2017-11-16       Impact factor: 4.256

5.  Cell division cycle 7 kinase is a negative regulator of cell-mediated collagen degradation.

Authors:  Michael J Podolsky; Deepti Gupta; Arnold Ha; Ryan Ta; Amin Khalifeh-Soltani; William McKleroy; Ritwik Datta; Dean Sheppard; Kamran Atabai
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2018-05-24       Impact factor: 5.464

6.  Overexpression of periostin is significantly correlated to the tumor angiogenesis and poor prognosis in patients with esophageal squamous cell carcinoma.

Authors:  Wei Wang; Qi-Kai Sun; Yi-Fu He; Dong-Chun Ma; Ming-Ran Xie; Chu-Shu Ji; Bing Hu
Journal:  Int J Clin Exp Pathol       Date:  2014-01-15

7.  Per2 inhibits k562 leukemia cell growth in vitro and in vivo through cell cycle arrest and apoptosis induction.

Authors:  Cheng-ming Sun; Shi-feng Huang; Jian-ming Zeng; Din-bing Liu; Qing Xiao; Wen-jun Tian; Xi-dan Zhu; Zong-gan Huang; Wen-li Feng
Journal:  Pathol Oncol Res       Date:  2009-12-03       Impact factor: 3.201

8.  Periostin is up-regulated in high grade and high stage prostate cancer.

Authors:  Verena Tischler; Florian R Fritzsche; Peter J Wild; Carsten Stephan; Hans-Helge Seifert; Marc-Oliver Riener; Thomas Hermanns; Ashkan Mortezavi; Josefine Gerhardt; Peter Schraml; Klaus Jung; Holger Moch; Alex Soltermann; Glen Kristiansen
Journal:  BMC Cancer       Date:  2010-06-09       Impact factor: 4.430

9.  Inverse correlation between PDGFC expression and lymphocyte infiltration in human papillary thyroid carcinomas.

Authors:  Ove Bruland; Øystein Fluge; Lars A Akslen; Hans G Eiken; Johan R Lillehaug; Jan E Varhaug; Per M Knappskog
Journal:  BMC Cancer       Date:  2009-12-08       Impact factor: 4.430

10.  Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas.

Authors:  J M Pita; A Banito; B M Cavaco; V Leite
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.